Sibylla Biotech

Trento, Italy Founded: 2017 • Age: 9 yrs
AI-powered platform for drug discovery

About Sibylla Biotech

Sibylla Biotech is a company based in Trento (Italy) founded in 2017 by Lidia Pieri.. Sibylla Biotech has raised $25.19 million across 2 funding rounds from investors including V-Bio Ventures, Seroba Lifesciences and 3B Future Health Fund. Sibylla Biotech offers products and services including PPI-FIT Platform and Oneiros AI Platform. Sibylla Biotech operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.

  • Headquarter Trento, Italy
  • Founders Lidia Pieri
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sibylla Biotech S.P.A.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25.19 M (USD)

    in 2 rounds

  • Latest Funding Round
    $22.55 M (USD), Series A

    Oct 04, 2022

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Sibylla Biotech

Sibylla Biotech offers a comprehensive portfolio of products and services, including PPI-FIT Platform and Oneiros AI Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

AI-based tool for targeting protein folding in therapeutic development.

System for simulating protein folding to support drug discovery efforts.

Funding Insights of Sibylla Biotech

Sibylla Biotech has successfully raised a total of $25.19M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $22.55 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $22.5M
  • First Round

    (15 Oct 2019)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2022 Amount Series A - Sibylla Biotech Valuation V-Bio Ventures
Oct, 2019 Amount Seed - Sibylla Biotech Valuation Vertis SGR
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Sibylla Biotech

Sibylla Biotech has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include V-Bio Ventures, Seroba Lifesciences and 3B Future Health Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
V-Bio Ventures is engaged in life science venture capital investment.
Founded Year Domain Location
Early-stage healthcare investments are made by 3B Future Health Fund.
Founded Year Domain Location
Claris Ventures is engaged in early-stage biotech venture investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Sibylla Biotech

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Sibylla Biotech

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sibylla Biotech Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Sibylla Biotech

Sibylla Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
An agentic AI platform is developed for biomedical research insights.
domain founded_year HQ Location
AI-powered drug discovery platform for various diseases
domain founded_year HQ Location
AI-based technology is used for recombinant protein production in therapeutics.
domain founded_year HQ Location
Antibody therapies are developed through machine learning and synthetic biology.
domain founded_year HQ Location
AI-based platform for cancer diagnostics and precision medicine is utilized.
domain founded_year HQ Location
AI platform used for extracting antibody data from scientific papers.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sibylla Biotech

Frequently Asked Questions about Sibylla Biotech

When was Sibylla Biotech founded?

Sibylla Biotech was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Sibylla Biotech located?

Sibylla Biotech is headquartered in Trento, Italy. It is registered at Trento, Trentino-alto Adige, Italy.

Who is the current CEO of Sibylla Biotech?

Lidia Pieri is the current CEO of Sibylla Biotech. They have also founded this company.

Is Sibylla Biotech a funded company?

Sibylla Biotech is a funded company, having raised a total of $25.19M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.65M, raised on Oct 15, 2019.

What does Sibylla Biotech do?

Sibylla Biotech was founded in 2017 in Trento, Italy, within the biotechnology sector. An AI-driven platform is employed for drug discovery, utilizing the Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) approach. Small molecules are identified and developed to act on targets such as Cyclin D1 and KRAS, addressing oncology and inflammatory diseases through its pipeline.

Who are the top competitors of Sibylla Biotech?

Sibylla Biotech's top competitors include Owkin, Formation Bio and XtalPi.

What products or services does Sibylla Biotech offer?

Sibylla Biotech offers PPI-FIT Platform and Oneiros AI Platform.

Who are Sibylla Biotech's investors?

Sibylla Biotech has 9 investors. Key investors include V-Bio Ventures, Seroba Lifesciences, 3B Future Health Fund, Claris Ventures, and CDP Venture Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available